Product Information

IMATINIB MESYLATE 100 MG TAB is a generic product labeled by Archis Pharma LLC, priced at $0.6114 per EA under NDC 72819018509. Its NADAC has been published 177 times since Apr 5, 2023.

FDA first approved this application on Jun 21, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

IMATINIB MESYLATE 100 MG TAB

imatinib mesylate
$0.6114per EA

Strength

100 mg/1

Manufacturer

Archis Pharma LLC

NDC

72819018509

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

IMATINIB MESYLATE

Approval Type

Generic (ANDA)

FDA Application

ANDA212135

FDA Approved

6/21/2022

TE Code

AB

On Market Since

9/1/2022

Pharmacological Classes

Bcr-Abl Tyrosine Kinase Inhibitors
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Kinase Inhibitor

Price Statistics

The NADAC for IMATINIB MESYLATE 100 MG TAB has been published 177 times since Apr 5, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$0.6114 per EA
All-time high$0.9761 (Sep 10, 2025)
All-time low$0.3890 (May 22, 2024)
52-week high$0.9761
52-week low$0.6114
Median price$0.6177
Average price$0.6925
Largest weekly change-35.6% (May 22, 2024)
Weeks tracked177
Tracking sinceApr 5, 2023

Price History

1W

-1.0%

1M

-7.8%

3M

-17.4%

6M

-28.3%

1Y

-37.4%

3Y

+0.4%

5Y

N/A

All

+0.4%

Generic Alternatives

The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 20% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of IMATINIB MESYLATE 100 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 100 MG TAB, manufactured by Archis Pharma LLC, is $0.6114 per EA (NDC 72819018509), effective Aug 19, 2026.

How has the price of IMATINIB MESYLATE 100 MG TAB changed over time?

Over the history we have for it, the NADAC for IMATINIB MESYLATE 100 MG TAB has held within roughly two percent of its current level. It has been tracked across 177 weekly CMS publications since Apr 5, 2023.

What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 100 MG TAB?

Since Apr 5, 2023, the NADAC for IMATINIB MESYLATE 100 MG TAB has ranged from a low of $0.3890 (May 22, 2024) to a high of $0.9761 (Sep 10, 2025), with a median of $0.6177 per EA.

Are there cheaper alternatives to IMATINIB MESYLATE 100 MG TAB?

Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMATINIB MESYLATE 100 MG TAB, is $0.4912 per EA — about 20% below IMATINIB MESYLATE 100 MG TAB.

Who manufactures IMATINIB MESYLATE 100 MG TAB?

IMATINIB MESYLATE 100 MG TAB (NDC 72819018509) is labeled by Archis Pharma LLC, and CMS classifies it as a generic product.